Business
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare ConferenceLocation: New York, NYFormat: Fireside chat and one-on-one investor meetingsDate: Friday, September 5, 2025Time: 10:55 a.m. ET Baird Global Healthcare Conference
About this update from Climb Bio, Inc.
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below. Cantor Global Healthcare Conference Location: New York, NY Format: Fireside chat and one-on-one investor meetings Date: Friday, September 5, 2025 Time: 10:55 a.m. ET Baird Global Healthcare Conference Location: New York, NY Format: Fireside chat and one-on-one investor meetings Date: Tuesday, September 9, 2025 Time: 4:20 PM p.m. ET Morgan Stanley Annual Global Healthcare Conference Location: New York, NY Format: One-on-one meetings only Date: Wednesday, September 10, 2025 Stifel Virtual Immunology and Inflammation Forum Location: Virtual Format: Presentation and one-on-one investor meetings Date: Tuesday, September 16, 2025 Time: 10:30 a.m. ET The live webcasts will be accessible via the “Investors and News” section of the Climb Bio website: https://ir.climbbio.com/ . Webcast replays will be available on the Climb Bio website beginning approximately two hours after each webcast event and will be archived for at least 30 days. About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com . Investors and Media Carlo Tanzi, Ph.D. Kendall Investor Relations [email protected]